Drug intelligence / Profile preview

BSCgal

Development stage: Preclinical
Lead developer: Stanford University
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems

Overview

BSCgal is an experimental nanomedicine platform composed of **reversibly crosslinked cationic gold nanoclusters and siRNA complexes in a polymer matrix** that is designed to **biodegrade over weeks**. This composite material enables localized delivery of small interfering RNA (siRNA), typically for preclinical or experimental therapeutic purposes. Its structure is optimized to enhance drug-radiotherapy combinations and controlled release, offering potential applications in cancer treatment or similar therapeutic contexts[7][8].

Targets

LGALS1 (Galectin-1)

Beyond the preview

Go deeper on BSCgal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSCgal.

Explore the full profile